Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.IntelliCell Biosciences has licensed its proprietary, patent pending technology for the manufacture of stromal vascular fraction (SVF) from adipose tissue to RegenaStem.
Subscribe to our email newsletter
The process involves non-enzymatic method for deriving stromal vascular fraction from 60cc’s of adipose tissue, which is believed to increase the yield in manufacturing stromal vascular fraction compared to the present enzymatic methods.
IntelliCell claims that its technology generates between 0.5bn to 1.4bn SVFC cells from 60 ccs from a patient’s own adipose tissue.
The terms of the licensing deal include, investing a minimum of $500,000 to a maximum of $1.5m into IntelliCell BioSciences and paying royalties of 30% of net revenue.
IntelliCell BioSciences based in Canada is focused on servicing the regenerative medicine market by providing IntelliCell technology.